



## Appendix 4D

### SIRTEX MEDICAL LIMITED

ABN 35 078 166 122

### Interim report – half year ended 31 December 2015

(Previous corresponding period: half year ended 31 December 2014)

#### Results for announcement to the market

	<b>% change</b>	<b>\$ 000</b>
Revenue from ordinary activities	up 40.0 %	112,596
Profit from ordinary activities after tax attributable to members	up 46.9 %	25,939
Total comprehensive income for the period attributable to members	up 50.8 %	27,437

#### Dividends (Distributions)

	<b>2015</b>	<b>2014</b>
Final dividend (paid on 21 October 2015 for financial year ended 30 June 2015)		
amount per security	20.0 cents	14.0 cents
franked amount per security	20.0 cents	14.0 cents
Interim dividend		
amount per security	Nil	Nil
franked amount per security	Nil	Nil

#### NTA Backing

	<b>2015</b>	<b>2014</b>
Net tangible asset backing per ordinary security	148.8 cents	102.7 cents

# Interim Financial Report

FOR THE HALF-YEAR ENDED 31 DECEMBER 2015

SIRTEX MEDICAL LTD AND ITS CONTROLLED ENTITIES  
ABN 35 078 166 122

<b>Directors' Report</b>	<b>2</b>
<b>Auditor's Independence Declaration</b>	<b>4</b>
<b>Directors' Declaration</b>	<b>5</b>
<b>Independent Auditor's Review Report</b>	<b>6</b>
<b>Consolidated Statement of Profit or Loss and Other Comprehensive Income</b>	<b>8</b>
<b>Consolidated Statement of Financial Position</b>	<b>9</b>
<b>Consolidated Statement of Changes in Equity</b>	<b>10</b>
<b>Consolidated Statement of Cash Flows</b>	<b>11</b>
<b>Notes to the Financial Statements</b>	<b>12</b>

# Directors' Report

for the half-year ended 31 December 2015

Your Directors submit the financial report of the consolidated entity for the half-year ended 31 December 2015.

## Directors

The names of Directors who held office during or since the end of the half-year:

R. Hill (Non-executive director, Chairman)

Dr J. Eady (Non-executive director, Deputy Chairman)

G. Boyce (Non-executive director)

Dr K. Woodthorpe (Non-executive director, appointed 22 September 2015)

G. Wong (Executive director, Chief Executive Officer)

## Principal activities

Sirtex Medical Limited and its controlled entities ("Group") form a medical device group whose primary objective is to manufacture and to distribute effective liver cancer treatments utilising small particle technology to approved markets in Asia-Pacific, Europe, Middle East and Africa, North and South America.

## Review of Operations

The Group's main product, called SIR-Spheres microspheres, is a targeted radioactive treatment for liver cancer. This treatment is called Selective Internal Radiation Therapy (SIRT) being a minimally invasive surgical procedure performed by an interventional radiologist. The SIR-Spheres microspheres lodge in the small blood vessels of the tumour where they destroy it from the inside over a short period while sparing the surrounding healthy tissue. During the half-year, the Group sold 5,728 doses worldwide representing less than 2% of the addressable market.

Dose sales for the half-year ended 31 December 2015 increased by 15.7% over the same period last financial year. North and South America (Americas) achieved growth of 18.8% with 4,028 doses, the European, Middle East and Africa (EMEA) market achieved growth of 8.8% with 1,219 doses, and Asia Pacific (APAC) recorded 481 dose sales representing growth of 9.3%.

The Group recorded sales revenue of \$112,596,000 for the half-year ended 31 December 2015. This represents an increase of 40.0% over the corresponding period last financial year (\$80,452,000). The higher sales revenue growth compared to volume growth is a result of changes in geographic revenue mix with stronger growth in the high margin US region, and of positive foreign currency fluctuations, as the Australia Dollar depreciated against the US dollar during the period.

Gross profit increased to 84.9% for the half-year ended 31 December 2015, compared to 84.3% for the corresponding period last financial year. The improvement was the result of higher manufacturing volumes and a better sales mix, with higher dose sales growth in countries with higher sales prices.

Profit before tax has improved 38.6% to \$33,156,000 for the half-year ended 31 December 2015 (31 December 2014: \$23,925,000), and Profit after tax has increased by 46.9% to \$25,939,000 (31 December 2014: \$17,655,000).

# Directors' Report

for the half-year ended 31 December 2015

Earnings per share for the half-year ended 31 December 2015 have increased to \$0.454 (2014: \$0.313). During the half-year ended 31 December 2015, a final dividend has been paid in respect of the previous financial year. The fully franked dividend was \$0.20 per share, representing an increase of 42.9% over the previous dividend paid.

A significant part of the Group's clinical activities is focused on five major Phase IV post-marketing clinical studies. One study was completed on 1 June 2015 and amortisation of the asset commenced. At half-year end, the remaining useful life on the trial was 89 months. Consistent with last year, expenses for the incomplete studies have been capitalised as they continue to satisfy the recognition criteria for AASB 138 Intangible Assets. Additions to capitalised costs incurred for these trials as well as for two smaller development projects during the half-year ended 31 December 2015 represent a total of \$7,696,000 compared to \$10,255,000 for the corresponding period of the previous financial year.

## **Rounding of Amounts**

The consolidated entity has applied the relief available to it in ASIC Class Order 98/100 and accordingly certain amounts in the financial report and the directors' report have been rounded off to the nearest \$1,000.

## **Events after Reporting Date**

No matters or circumstances have arisen since the end of the half year, that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

## **Auditor's Independence Declaration**

The lead auditor's independence declaration under section 307C of the Corporations Act 2001 is set out on page 4 for the half year ended 31 December 2015 and forms part of this report.

This report is signed in accordance with a resolution of the Board of Directors.



Gilman Wong

Director

24 February 2016



# Grant Thornton

Level 17, 383 Kent Street  
Sydney NSW 2000

Correspondence to:  
Locked Bag Q800  
QVB Post Office  
Sydney NSW 1230

T +61 2 8297 2400  
F +61 2 9299 4445  
E [info.nsw@au.gt.com](mailto:info.nsw@au.gt.com)  
W [www.grantthornton.com.au](http://www.grantthornton.com.au)

## **Auditor's Independence Declaration To The Directors of Sirtex Medical Limited**

In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of Sirtex Medical Limited for the half-year ended 31 December 2015, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- b no contraventions of any applicable code of professional conduct in relation to the review.

GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants

N.J. Bradley  
Partner - Audit & Assurance

Sydney, 24 February 2016

Grant Thornton Audit Pty Ltd ACN 130 913 594  
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.

# Directors' Declaration for the half-year ended 31 December 2015

The directors of the company declare that:

1. The consolidated financial statements and notes, as set out on page 8 to 17, are in accordance with the Corporations Act 2001, including:
  - a. complying with Accounting Standard AASB 134: Interim Financial Reporting; and
  - b. giving a true and fair view of the consolidated entity's financial position as at 31 December 2015 and of its performance for the half year ended on that date.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

A handwritten signature in blue ink, appearing to read 'Gilman Wong', with a stylized flourish at the end.

Gilman Wong  
Director

24 February 2016

Level 1,  
67 Greenhill Rd  
Wayville SA 5034  
GPO Box 1270  
Adelaide SA 5001  
T 61 8 8372 6666  
F 61 8 8372 6677  
E [info@gttsa.com.au](mailto:info@gttsa.com.au)  
W [www.grantthornton.com.au](http://www.grantthornton.com.au)

## **Independent Auditor's Review Report To the Members of Sirtex Medical Limited**

We have reviewed the accompanying interim financial report of Sirtex Medical Limited ("Company"), which comprises the consolidated financial statements being the statement of financial position as at 31 December 2015, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a statement or description of accounting policies, other explanatory information and the directors' declaration of the consolidated entity, comprising both the Company and the entities it controlled at the half-year's end or from time to time during the half-year.

### **Directors' responsibility for the half-year financial report**

The directors of Sirtex Medical Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such controls as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

### **Auditor's responsibility**

Our responsibility is to express a conclusion on the consolidated half-year financial report based on our review. We conducted our review in accordance with the Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the interim financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the Sirtex Medical Limited consolidated entity's financial position as at 31 December 2015 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations

Grant Thornton Audit Pty Ltd ACN 130 913 594  
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.

Regulations 2001. As the auditor of Sirtex Medical Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of an interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Independence**

In conducting our review, we complied with the independence requirements of the Corporations Act 2001.


### **Conclusion**

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Sirtex Medical Limited is not in accordance with the Corporations Act 2001, including:

- a giving a true and fair view of the consolidated entity's financial position as at 31 December 2015 and of its performance for the half-year ended on that date; and
- b complying with Accounting Standard AASB 134 Interim Financial Reporting and Corporations Regulations 2001.



GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants



N.J. Bradley  
Partner – Audit & Assurance

Sydney, 24 February 2016



# Consolidated Statement of Profit or Loss and Other Comprehensive Income

for the half-year ended 31 December 2015

	Note	Consolidated	
		31 Dec 2015 \$'000	31 Dec 2014 \$'000
Revenue from the sale of goods		112,596	80,452
Cost of sales		(16,949)	(12,636)
<b>Gross profit</b>		<b>95,647</b>	<b>67,816</b>
Other revenue		1,162	1,016
Marketing expenses		(39,563)	(29,464)
Research expenses		(4,713)	(2,944)
Regulatory expenses		(736)	(582)
Quality assurance expenses		(1,190)	(835)
Clinical expenses		(5,426)	(2,963)
Medical expenses		(2,966)	(1,856)
Administration expenses		(9,529)	(7,732)
Impairment expenses		(277)	-
Foreign exchange gains		747	1,469
<b>Profit before income tax expense</b>	<b>3</b>	<b>33,156</b>	<b>23,925</b>
Income tax expense		(7,217)	(6,270)
<b>Profit attributable to members of the parent entity</b>		<b>25,939</b>	<b>17,655</b>
<b>Other comprehensive income</b>			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation (net of tax) of foreign operations		1,262	536
<b>Total comprehensive income attributable to members of the parent entity</b>		<b>27,201</b>	<b>18,191</b>
<b>Earnings per share</b>		<b>Cents</b>	<b>Cents</b>
Basic earnings per share	4	45.4	31.3
Diluted earnings per share	4	44.6	30.5

The financial statements should be read in conjunction with the accompanying notes

# Consolidated Statement of Financial Position

as at 31 December 2015

		Consolidated	
	Note	31 Dec 15 \$'000	30 Jun 15 \$'000
<b>CURRENT ASSETS</b>			
Cash and cash equivalents		21,738	21,941
Other short-term deposits		52,000	52,000
Trade and other receivables		45,449	35,000
Inventories		1,629	1,836
Financial assets		1,560	1,213
Other assets		3,349	3,210
<b>Total - CURRENT ASSETS</b>		<b>125,725</b>	<b>115,200</b>
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment		14,144	13,164
Intangible assets	2	74,861	68,027
Deferred tax assets		5,630	5,085
<b>Total - NON-CURRENT ASSETS</b>		<b>94,635</b>	<b>86,276</b>
<b>TOTAL ASSETS</b>		<b>220,360</b>	<b>201,476</b>
<b>LIABILITIES</b>			
<b>CURRENT LIABILITIES</b>			
Trade and other payables		20,013	24,290
Current tax liabilities		3,855	4,746
Short-term provisions		7,801	6,666
<b>Total - CURRENT LIABILITIES</b>		<b>31,669</b>	<b>35,702</b>
<b>NON-CURRENT LIABILITIES</b>			
Long-term provisions		1,127	1,104
Deferred tax liabilities		21,928	20,034
<b>Total - NON-CURRENT LIABILITIES</b>		<b>23,055</b>	<b>21,138</b>
<b>TOTAL LIABILITIES</b>		<b>54,724</b>	<b>56,840</b>
<b>NET ASSETS</b>		<b>165,636</b>	<b>144,636</b>
<b>EQUITY</b>			
Issued capital		32,325	27,021
Reserves		6,804	5,615
Retained earnings		126,507	112,000
<b>TOTAL EQUITY</b>		<b>165,636</b>	<b>144,636</b>

The financial statements should be read in conjunction with the accompanying notes

# Consolidated Statement of Changes in Equity

for the half-year ended 31 December 2015

	Ordinary Shares	Share rights Reserve	FX Translation Reserve	Retained Profits	Total
	\$'000	\$'000	\$'000	\$'000	\$'000
<b>Balance at 1 July 2014</b>	<b>24,893</b>	<b>2,774</b>	<b>347</b>	<b>79,569</b>	<b>107,583</b>
Foreign currency translation reserve	-	-	536	-	536
Profit attributable to members of parent entity	-	-	-	17,655	17,655
Ordinary shares issued	948	(948)	-	-	-
Deferred tax on performance rights	677	-	-	-	677
Purchase of Non-Executive Directors' shares on market	(92)	-	-	-	(92)
Contribution to Performance Rights Reserve	-	1,009	-	-	1,009
Dividends paid or provided for	-	-	-	(7,913)	(7,913)
<b>Balance at 31 December 2014</b>	<b>26,426</b>	<b>2,835</b>	<b>883</b>	<b>89,311</b>	<b>119,455</b>
<b>Balance at 1 July 2015</b>	<b>27,021</b>	<b>4,075</b>	<b>1,540</b>	<b>112,000</b>	<b>144,636</b>
Foreign currency translation reserve	-	-	1,262	-	1,262
Profit attributable to members of parent entity	-	-	-	25,939	25,939
Ordinary shares issued	1,728	(1,728)	-	-	-
Deferred tax on performance rights	3,776	-	-	-	3,776
Purchase of Non-Executive Directors' shares on market	(200)	-	-	-	(200)
Contribution to Performance Rights Reserve	-	1,655	-	-	1,655
Dividends paid or provided for	-	-	-	(11,432)	(11,432)
<b>Balance at 31 December 2015</b>	<b>32,325</b>	<b>4,002</b>	<b>2,802</b>	<b>127,507</b>	<b>165,636</b>

The financial statements should be read in conjunction with the accompanying notes

# Consolidated Statement of Cash Flows

for the half-year ended 31 December 2015

	Consolidated	
	31 Dec 2015	31 Dec 2014
	\$'000	\$'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Receipts from customers	102,825	75,745
Payments to suppliers and employees	(78,933)	(52,367)
Interest received	1,278	1,167
Net income tax paid	(2,981)	(2,597)
<b>Net cash provided by operating activities</b>	<b>22,189</b>	<b>21,948</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Investment in / purchase of short-term deposits	-	(12,000)
Purchase of plant and equipment	(2,114)	(633)
Purchase of intangible assets	(1,340)	(187)
Internally generated intangible assets	(7,696)	(10,255)
<b>Net cash used in investing activities</b>	<b>(11,150)</b>	<b>(23,075)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Payment of dividends	(11,432)	(7,913)
<b>Net cash used in financing activities</b>	<b>(11,432)</b>	<b>(7,913)</b>
<b>Decrease in cash held</b>	<b>(393)</b>	<b>(9,040)</b>
<b>Cash at beginning of the financial period (1)</b>	<b>21,941</b>	<b>22,495</b>
Exchange differences on cash and cash equivalents	190	-
<b>Cash at end of the financial period (1)</b>	<b>21,738</b>	<b>13,455</b>

(1) Cash at the end of the financial period excludes term deposits held with a maturity date of greater than 90 days after the end of the financial period. These are described as "other short term deposits" in the Consolidated Statement of Financial Position.

The financial statements should be read in conjunction with the accompanying notes

# Notes to the Financial Statements

for the half-year ended 31 December 2015

## NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Basis of preparation

These general purpose financial statements for the interim half-year reporting period ended 31 December 2015 have been prepared in accordance with requirements of the *Corporations Act 2001* and Australian Accounting Standards including AASB 134: Interim Financial Reporting, and are presented in Australian dollar (\$), which is the functional currency of the parent company.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Sirtex Medical Limited and its controlled entities (the Group). They do not include all of the information required in annual financial statements in accordance with Australian Accounting Standards, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2015 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Stock Exchange Listing Rules and the *Corporations Act 2001*.

### Estimates

When preparing the interim financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management. The judgements, estimates and assumptions made during the period ended 31 December 2015 were the same as those applied in the Group's last financial statements for the year ended 30 June 2015.

These financial statements were authorised for issue by the Board of Directors on 23 February 2016.

## NOTE 2: INTANGIBLE ASSETS

### Internally generated intangible assets

Internally generated intangible assets include five major Phase IV post-marketing clinical trials and two development projects aiming to improve the ease of use of SIR-Spheres microspheres. One study was completed on 1 June 2015 and amortisation of the asset commenced. Amortisation of \$1,503,716 has been recognised during the half year. At half-year end, the remaining useful life on the trial was 89 months.

As the activities of the incomplete trials satisfy the recognition criteria as set out below, expenses incurred during the half year for these activities have been classified as internally generated intangible assets and capitalised in the Statement of Financial Position, for a total of \$7,696,133.

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised if, and only if all of the following is demonstrated:

- The technical feasibility of completing the intangible asset so that it will be available for use or for sale
- The intention to complete the intangible asset and to use it or sell it
- The ability to use or to sell the intangible asset
- The intangible asset will generate future economic benefits
- Adequate technical, financial, and other resources to complete the development and to use or sell the intangible asset are available
- The expenditure attributable to the intangible asset during its development can be reliably measured

Following the initial recognition of the development expenditure, the cost model is applied requiring the assets to be carried at cost less accumulated amortisation and accumulated impairment losses. Current capitalised development costs are to be amortised over 8 years.

# Notes to the Financial Statements

for the half-year ended 31 December 2015

## NOTE 2: INTANGIBLE ASSETS (continued)

The Consolidated Entity uses its judgment in continually assessing whether development expenditure meets the recognition criteria on an intangible asset.

At 31 December 2015, the assessment of all development activities resulted in the recognition of certain development expenditure as an internally generated intangible asset.

The carrying value of an intangible asset arising from development costs is tested for impairment annually when the asset is not yet available for use or more frequently when an indicator of impairment arises during the reporting period.

	Consolidated	
	31 Dec 15 \$'000	30 Jun 15 \$'000
Total intangible assets		
At cost	81,096	72,060
Accumulated amortisation	(6,235)	(4,033)
Net carrying amount	74,861	68,027

### Movements in carrying amounts

Total intangible assets		
Carrying amount at beginning	68,027	47,364
Additions	9,036	21,123
Amortisation expense	(2,202)	(460)
Carrying amount at end	74,861	68,027

## NOTE 3: PROFIT FOR THE PERIOD

	Consolidated	
	31 Dec 15 \$'000	31 Dec 14 \$'000
Profit before income tax includes the following items of income / (expenses):		
Cost of sales	(16,949)	(12,636)
Bad and doubtful debts expense	277	115
Depreciation and amortisation of plant and equipment	(1,134)	(831)
intangible assets*	(2,202)	(91)
Operating lease expenses		
minimum lease payments	(1,226)	(1,250)
Foreign exchange gains / (losses)		
realised foreign exchange gains / (losses)	225	549
unrealised foreign exchange gains / (losses)	522	920

\* includes internally generated intangible assets and purchased intangible assets

# Notes to the Financial Statements

for the half-year ended 31 December 2015

## NOTE 4: EARNINGS PER SHARE

	Consolidated	
	31 Dec 15 \$	31 Dec 14 \$
<b>(a) Basic earnings per share</b>		
Profit from continuing operations attributable to equity holders	25,939,000	17,655,000
Weighted average number of shares used in the calculation of basic earnings per share	57,106,101	56,491,707
Add to number of shares used in the calculation of diluted earnings per share:		
Effect of potential conversion to ordinary shares from the Executive Performance and the Non-Executive Directors' Rights Plan	1,002,494	1,479,770
<b>(b) Diluted earnings per share</b>		
Profit from continuing operations attributable to equity holders	25,939,000	17,655,000
Weighted average number of shares used in the calculation of diluted earnings per share	58,108,595	57,971,477

## NOTE 5: SHARE CAPITAL

During the period ended 31 December 2015, a total of 693,688 shares were issued as a result of the exercise of performance rights vested. The weighted average share price at the date of issue was \$30.15 during the first six months (2014: \$19.22). Each share has the same right to receive dividends and the repayment of capital and represents one vote at the shareholders' meeting. Shares issued and authorised are summarised as follows:

	Consolidated	
	6 months to 31 Dec 15	Year to 30 Jun 15
Shares issued and fully paid:		
Beginning of the period	56,530,231	56,108,439
Issued under share-based payment plans	693,688	421,792
<b>Shares issued and fully paid</b>	<b>57,223,919</b>	<b>56,530,231</b>
<b>Total shares authorised at the end of the period</b>	<b>57,223,919</b>	<b>56,530,231</b>

## NOTE 6: DIVIDENDS

	Consolidated	
	31 Dec 15 \$'000	31 Dec 14 \$'000
Distributions paid/provided for		
Fully franked ordinary dividend paid on 21 October 2015 of 20 cents (2014: 14 cents) per share	11,432	7,913

# Notes to the Financial Statements

for the half-year ended 31 December 2015

## NOTE 7: OPERATING SEGMENT

### Identification of reportable segments

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors in assessing performance and determining the allocation of resources.

The Group is managed primarily on the basis of regional markets which have different structures and performance as assessment criteria. Operating segments are therefore determined on the same basis. The three regional markets currently serviced by the group are Asia Pacific (APAC), North and South America (Americas) and Europe, Middle East and Africa (EMEA).

As the group manufactures and distributes only one product, identical for each of the three regional markets, no further segmentation across products or services is made.

### Basis of accounting for purposes of reporting by operating segments

#### Accounting policies adopted

Unless stated otherwise, all amounts reported to the Board of Directors with respect to operating segments are determined in accordance with accounting policies that are consistent to those adopted in the annual financial statements of the Group.

#### Inter-segment transactions

An internally determined transfer price is set for all inter-entity sales. This price is re-set annually and is based on what would be realised in the event the sale was made to an external party at arm's length. All such transactions are eliminated on consolidation for the Group's financial statements.

Inter-segment loans payable and receivable are initially recognised at the consideration received net of transaction costs. If inter-segment loans are not on commercial terms, these are not adjusted to fair value based on market interest rates. This policy represents a departure from that applied to the statutory financial statements.

#### Segment assets

Where an asset is used across multiple segments, the asset is allocated to the segment that received the majority of economic value from the asset. In the majority of instances, segment assets are clearly identifiable on the basis of their nature and physical location.

#### Segment liabilities

Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to the Group as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

### Segment performance

#### Segment revenue

For 6 months to 31 Dec 15 and 31 Dec 14	External Sales		Inter-segment(s)		Total	
	2015	2014	2015	2014	2015	2014
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
APAC	4,088	3,207	142,490	67,787	146,578	70,994
Americas	89,435	61,220	9,745	5,759	99,180	66,979
EMEA	19,073	16,025	32,215	495	51,288	16,520
<b>Total of all segments</b>					<b>297,046</b>	<b>154,493</b>
Interest					1,039	896
Eliminations					(184,450)	(74,041)
Other					123	120
<b>Consolidated</b>					<b>113,758</b>	<b>81,468</b>



# Notes to the Financial Statements

for the half-year ended 31 December 2015

## NOTE 7: OPERATING SEGMENT (continued)

### Segment net profit before tax

	2015 \$'000	2014 \$'000
APAC	7,415	22,967
Americas	1,972	789
EMEA	23,769	169
<b>Total of all segments</b>	<b>33,156</b>	<b>23,925</b>
Eliminations	-	-
<b>Profit before income tax expense</b>	<b>33,156</b>	<b>23,925</b>
Income tax expense	(7,217)	(6,270)
<b>Profit after income tax expense</b>	<b>25,939</b>	<b>17,655</b>

### Segment assets and liabilities

	Assets		Liabilities	
	31 Dec 15 \$'000	30 Jun 15 \$'000	31 Dec 15 \$'000	30 Jun 15 \$'000
APAC	232,282	244,707	93,590	100,128
Americas	59,507	44,687	40,975	30,083
EMEA	65,167	26,734	21,521	17,421
<b>Total of all segments</b>	<b>356,956</b>	<b>316,128</b>	<b>156,086</b>	<b>147,632</b>
Eliminations	(136,596)	(114,652)	(101,362)	(90,792)
<b>Consolidated</b>	<b>220,360</b>	<b>201,476</b>	<b>54,724</b>	<b>56,840</b>

### Other segment information

	Asia Pacific		North America		Europe	
	2015 \$'000	2014 \$'000	2015 \$'000	2014 \$'000	2015 \$'000	2014 \$'000
<b>Acquisition of segment assets</b>						
- Plant and equipment	740	358	994	127	380	148
- Intangibles	9,036	187	-	-	-	-
<b>Depreciation and amortisation of segment assets</b>						
- Plant and equipment	444	486	404	212	286	133
- Intangibles	2,201	91	-	-	1	-

# Notes to the Financial Statements

for the half-year ended 31 December 2015

## **NOTE 8: CONTINGENT LIABILITIES**

Litigation is in process against one of the companies in the Group relating to a dispute with a distributor whose agreement has been terminated. Management are not in a position to assess the likely outcome of the claim and accordingly cannot quantify the potential loss however management are of the opinion that any potential loss will not be material to the Group.

## **NOTE 9: EVENTS AFTER REPORTING DATE**

As at the date of this report, a total of 65,942 Executive Performance Rights have been exercised and issued as ordinary shares of Sirtex Medical Limited.

No other matter or circumstance has arisen since the end of the financial half year, that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.